Search clinical trials for: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

Total 110 results

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Completed

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

COVID-19

China
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

COVID-19

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological...

Active, not recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)

COVID-19

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

COVID-19

United Arab Emirates
Sinovac Biotech (Colombia) S.A.S.
Sinovac Life Sciences Co., Ltd.

Not yet recruiting

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

COVID-19

Colombia
China National Biotec Group Company Limited
The University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above (COVID-19)

COVID-19

Hong Kong
Sinovac Biotech (Hong Kong) Limited

Completed

Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Not yet recruiting

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for...

Active, not recruiting

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above (COVID-19)

COVID-19

China
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

COVID-19

Russian Federation, Nepal
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)

COVID-19

Philippines
WestVac Biopharma Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Mexico
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Recruiting

A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)

COVID-19

Uzbekistan
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention

Not yet recruiting

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

COVID-19
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

COVID-19

United Arab Emirates
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
WestVac Biopharma Co., Ltd.
West China Hospital

Completed

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

China
WestVac Biopharma Co., Ltd.

Completed

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Philippines
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China
Jiangsu Rec-Biotechnology Co., Ltd.
Iqvia Pty Ltd

Completed

Safety, Reactogenicity and Immunogenicity Study of ReCOV

Covid19

New Zealand
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Shulan (Hangzhou) Hospital

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above (COVID-19)

COVID-19

China
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
Sinovac Research and Development Co., Ltd.

Completed

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

COVID-19

China
WestVac Biopharma Co., Ltd.

Completed

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

COVID-19 | SARS-CoV-2 Pneumonia

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Beijing Chao Yang Hospital; The Second Affiliated Hospital of Chongqing Medical...

Unknown

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

Coronavirus

China
Zhongnan Hospital
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of...

Recruiting

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Unknown

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Unknown

Clinical Study of Recombinant Novel Coronavirus Vaccine

Coronavirus

China
CanSino Biologics Inc.

Withdrawn

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

COVID-19
Jiangsu Province Centers for Disease Control and...
West China Hospital

Withdrawn

Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

Coronavirus

China
AIM Vaccine Co., Ltd.
First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...

Active, not recruiting

A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

SARS-CoV-2

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Active, not recruiting

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Safety and Efficacy | Prevention of COVID-19

China, Ecuador, Indonesia, Pakistan, Uzbekistan
Catholic Kwandong University
Korea University Guro Hospital

Active, not recruiting

Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines

COVID-19 | Vaccine Reaction | Influenza | Contaminant Injected

Korea, Republic of
Public health and reforms Center of Ministry of...
World Health Organization; Ministry of Health of Azerbaijan Republic

Recruiting

Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan (VaccEffect)

Covid19 | Vaccine Refusal

Azerbaijan
Canadian Immunization Research Network
Massachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaborators

Active, not recruiting

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (MOSAIC)

COVID-19

Canada
WestVac Biopharma Co., Ltd.
West China Hospital

Not yet recruiting

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

COVID-19

China
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Active, not recruiting

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated (COVID-19)

Covid19

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
WestVac Biopharma Co., Ltd.
West China Hospital

Active, not recruiting

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

COVID-19

Philippines, Indonesia, Kenya, Mexico, Nepal
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Active, not recruiting

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

COVID-19

China
The Immunobiological Technology Institute (Bio-Manguinhos)...

Recruiting

Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

COVID-19

Brazil
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
The Immunobiological Technology Institute (Bio-Manguinhos)...

Active, not recruiting

Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.

COVID-19

Brazil
Yisheng Biopharma (Singapore) Pte. Ltd.

Completed

A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

COVID-19 Pandemic

United Arab Emirates
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China

Search clinical trials for: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations